| HOME >> BIOLOGY >> TECHNOLOGY |
Preference shareholders - (5,368)
Earnings per share for result
attributable to the equity holders of
the Company during the period
(expressed in Euro per share)
Basic and diluted earnings per share (1.28) (1.94)
Consolidated balance sheet
(after appropriation of result)
(In EUR x 1,000)
31 December 2007 31 December 2006
ASSETS
Non-current assets
Intangible assets 1,897 1,540
Property, plant and equipment 2,102 1,091
3,999 2,631
Current assets
Receivables from related parties 985 1,202
Social security and other taxes 714 276
Other receivables 1,211 51
Cash and cash equivalents 51,330 14,058
54,240 15,587
Total assets 58,239 18,218
EQUITY
Shareholders' equity 51,407 (1,682)
Total group equity 51,407 (1,682)
LIABILITIES
Non-current liabilities
Loans from related parties - 1,038
Liabilities to preference shareholders - 15,504
Financial lease liabilities 402 498
Other non-current liabilities 604 45
1,006 17,085
Current liabilities
Trade
'/>"/>
| SOURCE Amsterdam Molecular Therapeutics B.V Copyright©2008 PR Newswire. All rights reserved |